Description
ACADIA Pharmaceuticals’ Hidden ADP Catalyst: Why August To October Matters!
ACADIA Pharmaceuticals reported first quarter 2026 results showing moderate revenue growth and continued advancement of its pipeline programs. Total revenues reached $268 million, marking an 11% year-over-year increase on an adjusted basis. The company’s commercial performance was driven by its two main products, DAYBUE and NUPLAZID. DAYBUE generated $101 million in sales, a 20% increase compared to the prior year, attributed in part to the successful launch and broadening availability of DAYBUE STIX, a powder for oral solution formulation. Early adoption of DAYBUE STIX showed encouraging feedback from caregivers and healthcare providers, with over 250 prescriptions in the first quarter, including nearly 30% treatment-naive or returning patients. NUPLAZID sales were $167 million, reflecting 6% adjusted year-over-year growth. The quarter experienced some temporary delays in prescription refills, but demand and referral growth remained strong, with physicians increasing referrals by approximately 11%. The company completed a 30% expansion of its NUPLAZID sales force during the quarter, anticipated to enhance market penetration in the latter half of 2026 and beyond.
